The FDA altered its view of Sarepta Therapeutics Inc.’s data with exon-skipping therapy eteplirsen for Duchenne muscular dystrophy (DMD) after Prosensa Holding NV’s failure with exon-skipper drisapersen for the condition, but Sarepta CEO Chris Garabedian hopes the agency can still be brought around.